As an adjunct therapy to diet to:
• Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors.
• Reduce the risk of MI and stroke in patients with Type 2 diabetes without CHD, but with multiple risk factors
• Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalizations for CHF, and angina in patients with CHD
• Reduce elevated total-C, LDL-C, apo B and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and non-familial) and mixed dyslipidemia.
• Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia
• Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH)
• Reduce elevated total-C, LDL-C, and apo B levels in boys and post menarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy.